July 23, 2012—The House health appropriations subcommittee has declined to include language in its fiscal 2013 funding bill for the Department of Health and Human Services (HHS) that would authorize the collection of user fees on 340B discounted drugs. Its July 18 action came about a month after the Senate Appropriations Committee passed an HHS spending bill that would authorize the fees.
A 340B user fee has been an important priority for the Health Resources and Services Administration (HRSA) for a number of years and would be used to finance its Office of Pharmacy Affairs (OPA).
You must be registered to read complete articles (it's quick, easy, and 100% free). Click here to register. Already registered? Click here to login. (340B Health members, Drug Discount Monitor subscribers, and 340B Coalition conference attendees: Use your existing username and password.)